280 related articles for article (PubMed ID: 20199125)
1. Pluripotent human stem cells: A novel tool in drug discovery.
Phillips BW; Crook JM
BioDrugs; 2010 Apr; 24(2):99-108. PubMed ID: 20199125
[TBL] [Abstract][Full Text] [Related]
2. The application of human embryonic stem cell technologies to drug discovery.
Sartipy P; Björquist P; Strehl R; Hyllner J
Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
[TBL] [Abstract][Full Text] [Related]
3. Human stem cells for modeling neurological disorders: accelerating the drug discovery pipeline.
Crook JM; Kobayashi NR
J Cell Biochem; 2008 Dec; 105(6):1361-6. PubMed ID: 18980214
[TBL] [Abstract][Full Text] [Related]
4. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
McGivern JV; Ebert AD
Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
[TBL] [Abstract][Full Text] [Related]
5. Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment.
Sartipy P; Björquist P
Stem Cells; 2011 May; 29(5):744-8. PubMed ID: 21433222
[TBL] [Abstract][Full Text] [Related]
6. Pluripotent human stem cells as novel tools in drug discovery and toxicity testing.
Sartipy P; Bjorquist P; Strehl R; Hyllner J
IDrugs; 2006 Oct; 9(10):702-5. PubMed ID: 17016777
[TBL] [Abstract][Full Text] [Related]
7. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
Giri S; Bader A
Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
[TBL] [Abstract][Full Text] [Related]
8. Cardiomyocytes derived from human pluripotent stem cells for drug screening.
Zeevi-Levin N; Itskovitz-Eldor J; Binah O
Pharmacol Ther; 2012 May; 134(2):180-8. PubMed ID: 22269465
[TBL] [Abstract][Full Text] [Related]
9. Stem cell models for drug discovery and toxicology studies.
Liu W; Deng Y; Liu Y; Gong W; Deng W
J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
[TBL] [Abstract][Full Text] [Related]
10. Pluripotent Stem Cell-Derived Human Tissue: Platforms to Evaluate Drug Metabolism and Safety.
Meseguer-Ripolles J; Khetani SR; Blanco JG; Iredale M; Hay DC
AAPS J; 2017 Dec; 20(1):20. PubMed ID: 29270863
[TBL] [Abstract][Full Text] [Related]
11. Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening.
Greenhough S; Medine CN; Hay DC
Toxicology; 2010 Dec; 278(3):250-5. PubMed ID: 20674645
[TBL] [Abstract][Full Text] [Related]
12. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.
Shaheen N; Shiti A; Gepstein L
Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902
[TBL] [Abstract][Full Text] [Related]
13. Labeled stem cells as disease models and in drug discovery.
Ellerström C; Strehl R; Hyllner J
Methods Mol Biol; 2013; 997():239-51. PubMed ID: 23546761
[TBL] [Abstract][Full Text] [Related]
14. Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.
Scott CW; Peters MF; Dragan YP
Toxicol Lett; 2013 May; 219(1):49-58. PubMed ID: 23470867
[TBL] [Abstract][Full Text] [Related]
15. Human pluripotent stem cells for genetic disease modeling and drug screening.
Gauthier M; Maury Y; Peschanski M; Martinat C
Regen Med; 2011 Sep; 6(5):607-22. PubMed ID: 21916596
[TBL] [Abstract][Full Text] [Related]
16. Can stem-cell-derived models revolutionize drug discovery?
Landgren H; Sartipy P
Expert Opin Drug Discov; 2014 Jan; 9(1):9-13. PubMed ID: 24308376
[TBL] [Abstract][Full Text] [Related]
17. Human iPSC-derived miniature organs: a tool for drug studies.
Takebe T; Taniguchi H
Clin Pharmacol Ther; 2014 Sep; 96(3):310-3. PubMed ID: 24848506
[TBL] [Abstract][Full Text] [Related]
18. Human pluripotent stem cells for disease modelling and drug screening.
Maury Y; Gauthier M; Peschanski M; Martinat C
Bioessays; 2012 Jan; 34(1):61-71. PubMed ID: 22038777
[TBL] [Abstract][Full Text] [Related]
19. iPS cell derived neuronal cells for drug discovery.
Heilker R; Traub S; Reinhardt P; Schöler HR; Sterneckert J
Trends Pharmacol Sci; 2014 Oct; 35(10):510-9. PubMed ID: 25096281
[TBL] [Abstract][Full Text] [Related]
20. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.
Csöbönyeiová M; Polák Š; Danišovič L
Can J Physiol Pharmacol; 2016 Jul; 94(7):687-94. PubMed ID: 27128322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
